DNA damage causes TP53-dependent coupling of self-renewal and senescence pathways in embryonal carcinoma cells by Jackson, T.R. et al.
  
 
 
 
 
Jackson, T.R., Salmina, K., Huna, A., Inashkina, I., Jankevics, E., Riekstina, 
U., Kalnina, Z., Ivanov, A., Townsend, P.A., Cragg, M.S., and Erenpreisa, 
J.  (2013) DNA damage causes TP53-dependent coupling of self-renewal 
and senescence pathways in embryonal carcinoma cells. Cell Cycle, 12 (3). 
pp. 430-441. ISSN 1538-4101 
 
 
Copyright © 2013 Landes Bioscience 
 
 
 
http://eprints.gla.ac.uk/74546/ 
 
 
 
 
Deposited on: 05 February 2013 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
Landes Bioscience www.landesbioscience.com
Supplemental Material to: 
Thomas R. Jackson, Kristine Salmina, Anda Huna,  
Inna Inashkina, Eriks Jankevics, Una Riekstina,  
Zane Kalnina, Andrey Ivanov, Paul A. Townsend,  
Mark S. Cragg and Jekaterina Erenpreisa
DNA damage causes TP53-dependent  
coupling of self-renewal and senescence  
pathways in embryonal carcinoma cells
 Cell Cycle 2012; 12(3)
http://dx.doi.org/10.4161/cc.23285
http://www.landesbioscience.com/journals/cc/article/23285
 
SF1. PA1 cells seeded into serum free media readily form non-adherent. 
OCT4/NANOG-positive spheric cell aggregates, indicating to the pluripotent (ES) cell 
properties of this cell line. Cells were stained for NANOG (green), OCT4AB (red) and 
counter stained with DAPI (Blue). Bar = 20 µm. Representative images from 2 
independent  experiments.  
 
 
 
SF2. Up-regulation of AURORA B kinase in response to ETO treatment assessed by 
IF in combination with DAPI (blue). (A) In non-treated PA1 cells AURORA B kinase 
(red)  labels centromeres of metaphase chromosomes and G2 cell nuclei; (B) In 
ETO- treated PA1 cells the enhanced AURORA B kinase staining is apparent in the 
majority of interphase cells arrested on day 2 in G2. This enhanced staining 
subsequently persists in most cells with large nuclei indicating to their mitotic 
potential. Bars = 10µm. Representative images from 6 independent experiments.  
 
SF3. Characteristics of macroautophagy and expression of OCT4A and telomerase 
(TERT) in different cell populations on day 5 post ETO treatment. PA-1 cells were 
treated with 8µM ETO for 20 hours, then washed and examined 5 days later. Fixed 
cells were stained for LC3B (red; panel A and F), OCT4A (green; panel B, C and D), 
P62 (red; panel C) or TERT (green; panel E and F) in combination with DAPI (blue). 
(A-D) Macroautophagy marked by LC3B and P62 is characteristic of large 
hypertrophic cells, possessing extensive OCT4A (white arrowheads) and not small 
diploid cells with relatively low OCT4A levels (yellow arrowheads) which are 
recovering and re-entering the mitotic cycle. These small diploid cell nuclei possess 
nuclear TERT foci (white arrowheads on E), testifying to their self-renewal potential. 
(E, F) Hypertrophic (presumably pre-senescent) cells undergoing enhanced 
macroautophagy release the chromatin-bound TERT in perinuclear autophagic 
vacuoles (yellow arrowheads), whilst accumulating large amounts of TERT in the 
cytosol. Both phenomena are indicative of an apoptosis-protective function, which 
may be supported by OCT4. Bars = 10µm. Representative images from 3 
independent experiments.  
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SF4. NANOG expression in PA-1 cells. PA-1 cells were treated with 8µM ETO for 20 
hours, then washed and examined by IF for A) OCT4A (red) or NANOG (green) and 
DAPI (blue) at day 5 or B) OCT4A (green) or NANOG (red) and DAPI (blue). A) 
NANOG outlines chromosomes in the mitoses and small clones of recovering cells. 
B) Rare NT cells display high levels of NANOG expression (white arrowheads). 
Large, presumably polyploid cells also have high levels of NANOG expression (white 
arrowheads). Bar = 10µm. Representative data from 7 independent experiments 
using either monoclonal or polyclonal anti-NANOG antibody.   
 
  
 
 
 
SF5. Expression levels of OCT4A and P21CIP1 in PA-1 cells in response to ETO 
treatment as determined using image cytometry. PA-1 cells were treated with 8µM 
ETO for 20 hours, then washed and analysed over time for OCT4A or P21CIP1 
expression in combination with DAPI. (A) The fluorescent intensity of P21CIP1 and 
OCT4A staining was determined by image cytometry and plotted against the DNA 
content for 50 cells. OCT4A (top) and P21CIP1 (bottom) have higher levels of 
expression in cells with ≥4C DNA content after ETO treatment. (B) Shows the 
median, inter quartile range, full range and outliers of the OCT4A (top) and P21CIP1 
(bottom) intensities on day 3, 4 and 6 after ETO treatment compared to NT controls 
(500 cells). Greatly increased heterogeneity in OCT4A and P21CIP1 content is 
evident after ETO treatment, with mean expression peaking on day 4. Data are 
representative of >3 independent experiments. 
 
 
SF6. Immunoblot analysis of TP53, pCHK2, OCT4A and P21CIP1 in PA-1 cells after 
ETO treatment. PA-1 cells were stably transfected with shRNA-P53 or control vector 
before treatment with 8µM ETO, washing after 20 hours, cell lysates generated and 
assessed by immunoblotting for pCHK2, TP53, P21CIP1, OCT4A or GAPDH as a 
loading control at the indicated time points. TP53 was up regulated in response to 
ETO treatment and suppressed by shRNA-TP53. P21CIP1 and OCT4A were also 
up-regulated by ETO treatment and the upregulation was restricted by silencing of 
TP53. pCHK2 accumulated in ETO treated cells and this accumulation was 
increased in TP53 silenced cells. Data are representative of 3 independent 
experiments. 
 
 
 
  
 
SF7. Immunoblot analysis of HA tagged OCT4A and OCT4-PG1 isoforms expressed 
in HEK 293T cells. 293T cells were transiently transfected with plasmids encoding 
HA tagged OCT4A and OCT4-PG1 isoforms. 24 hours later, cell lysates were made 
and immunoblotting performed for OCT4A or HA as a loading control. These data 
clearly show that the OCT4A antibody detects OCT4A but not OCT4-PG1. Data 
shown from a single experiment.  
  
 
 SF8. Effect of TP53-silencing on the dynamics of the cell cycle response to ETO in 
PA-1 cells. PA-1 cells transfected with siRNA-p53 or ntg control were treated with 
8µM ETO for 20 hours, then washed and examined by DNA image cytometry over 
time. siRNA-TP53 caused a larger accumulation of cells in the 4C fraction (which 
may be composed of (2N-G2, M, and 4N-G1 cells) and delayed recovery of the 
proliferatiing G1-2C fraction as compared with the ntg control ETO-treated cells on 
days 4 and 5.  Representative histograms from two independent experiments.  
 
 
 
SF9. Examples of normal and abnormal mitoses. Cells were pelleted, cytospun, fixed 
and stained for pCHK2 (red) and ɑ-tubulin (green) to allow analyses of centrosomes 
and spindles. The left panel shows normal bi-centrosomal/bi-polar mitosis in NT cells; 
the right panel shows multicentrosomal/multipolar dysregulated mitosis in ETO 
treated cells. Bar = 10µM. Representative images from 3 independent experiments.  
 
 
SF10. Examples of normal and aberrant mitoses in PA-1 cells before or after ETO 
treatment. PA-1 cells (A) or siRNAp53 treated cells (B-D) were untreated or treated 
with 8µM ETO for 20 hours, then washed and assessed by IF or stained with 
toluidine blue on day 4. For IF, fixed cytospins were stained for γH2AX (red; panel C 
and D), in combination with DAPI (blue). For DNA imaging cells were treated with 5N 
HCl and stained with toluidine blue.(A) normal metaphase plate; (B) highly aberrant 
mitosis stained for DNA after siRNA-p53 treatment; (C) aberrant mitosis with many 
chromosomes unattached to the spindle and possessing DNA damage as judged by 
γH2AX staining. (D) A cell with persistent DNA damage undergoing mitotic slippage, 
while the re-formation of the nuclear envelope leaves behind multiple micronuclei in 
the cytoplasm (arrowheads); Bar = 10 µm. Representative images from 4 
independent experiments.  
 
 
 
 
 
 
